The world’s first approved CRISPR-based gene therapy has produced what researchers are calling functional cures in 93.5% of sickle cell disease patients treated in the pivotal CLIMB SCD-121 trial, according to two-year follow-up data presented at the American Society of Hematology annual meeting.

About Sickle Cell Disease

Sickle cell disease (SCD) affects approximately 100,000 Americans and millions worldwide, predominantly of African, Mediterranean, Middle Eastern, and South Asian ancestry. The inherited mutation causes red blood cells to form rigid, sickle-shaped cells that block blood flow, causing severe pain crises (vaso-occlusive episodes, or VOEs), organ damage, stroke, and premature death. Average life expectancy with SCD is 20–30 years shorter than the general population.

How Casgevy Works

Casgevy uses CRISPR-Cas9 gene editing to modify patients’ own hematopoietic stem cells, reactivating fetal hemoglobin (HbF) — a form of hemoglobin that is naturally suppressed after birth but that does not sickle. By inactivating the BCL11A gene (which suppresses HbF), the therapy permanently reprograms the patient’s blood cell production to generate non-sickling hemoglobin.

The process involves collecting stem cells from the patient’s bone marrow, editing them in the laboratory over several weeks, then reinfusing them after the patient undergoes myeloablative conditioning chemotherapy to clear existing bone marrow.

Two-Year Results

Of 46 patients with at least 2 years of follow-up:

  • 93.5% (43/46) were free of severe VOE pain crises for at least 12 consecutive months
  • 100% achieved HbF levels above 20% — the threshold associated with protection from sickling
  • Mean HbF as a proportion of total hemoglobin: 39.2%
  • No patient required red blood cell transfusion after engraftment
  • No therapy-related serious adverse events; myeloablation-related toxicities as expected

“These are life-changing results for a disease that has devastated families and communities for generations. We are witnessing the beginning of the end of sickle cell disease as an inevitably progressive illness.”

— Dr. Stuart Orkin, Dana-Farber/Boston Children’s Cancer and Blood Disorders Center

The $2.2 Million Question

Casgevy is priced at $2.2 million per treatment — making it one of the most expensive therapies in history. While health economists argue that this may be cost-effective relative to a lifetime of hospitalizations and hydroxyurea therapy, insurers and Medicaid programs are struggling with coverage determinations. Several states are negotiating outcomes-based contracts with the manufacturer, Vertex and CRISPR Therapeutics.

Access Disparities

The irony is stark: a disease that disproportionately affects Black Americans and is chronically underfunded relative to its disease burden now has a cure — but one that may be inaccessible to the communities most affected. Patient advocacy groups are pushing for federal funding mechanisms and international licensing agreements to ensure global access.

⚕️ Medical Disclaimer: This article is for informational purposes only. It does not constitute medical advice. Always consult a qualified healthcare professional before making health decisions.